65,437 trials
Paroxysmal Atrial Fibrillation
Primary: Chronic Effectiveness in Treating PAF as Demonstrated by no AF Recurrences After the Blanking Period and During the 12-month Follow-up Period. — 42 Successful participants
Prostate Cancer · Sexual Dysfunction
Primary: Percentage of Patients Maintaining Spontaneous (Off-drug) Erectile Function (EF) at Weeks 28-30 After Initiation of Radiation Therapy (RT) — 79; 74 percentage of…
Bipolar I Disorder
Primary: Time to Recurrence of Mood Event During the Double Blind Treatment Phase — NA; 207 Days — p=<0.078
Oral Hygiene
Primary: Number of Gingival Bleeding Sites at 24 Weeks — 13.24; 24.90 Number of bleeding sites — p=<0.0001
Refractive Error
Primary: Percentage of Subjects With Wettability Grade of 2 or 3 After 12 Hours of Wear — 55.8; 47.2; 46.5; 49.5 percentage of subjects
Inflammatory Bowel Disease
Primary: Pediatric INTERMED- Complexity Index — 24; 9.0; 4.0; 4.0 scores on a scale
Pulmonary Sarcoidosis
Primary: Bronchoalveolar Lavage (BAL) and Peripheral Blood Mononuclear Cells (PBMC) TNF-α Levels — 40767; 39938; 45176; 25671 pg/ml
Hyperphosphatemia · Chronic Kidney Disease
Primary: Change From Baseline (Week 0) to Week 2 in Serum Phosphorus — 7.2; 7.2; 7.24; 6.34 mg/dL — p=0.001
Occupational; Cramp(s)
Primary: Mean Dynamic Change of Rotation at Impact — -38.4; -32.5; -36.5; NA degrees/sec
Healthy Volunteers
Primary: Cmax: Maximum Observed Plasma Concentration for TAK-385 — 46.7; 42.0; 33.0; 52.0 ng/mL
Hemophilia B
Primary: Maximum Observed Plasma Concentration (Cmax) — 0.3880; 0.4226 IU/milliliter (IU/mL)
Nonarteritic Anterior Ischemic Optic Neuropathy
Primary: Change in Visual Acuity — 4; 3 lines change in Snellen chart
Apnea
Primary: Mean Received Tidal Volume — 681; 591 milliliters
HIV Positive · Anal Condylomata · Anal Warts
Primary: The Primary Endpoint of This Study is Persistence and Recurrence of Anal Warts as Compared Between the Experimental and Control Groups. — 1; 1 participants
Leukaemia, Lymphocytic, Chronic
Primary: Progression-free Survival (PFS), as Assessed by the Independent Review Committee (IRC) — 28.94; 18.83 Months — p=0.0032